The FDA has granted accelerated approval to dostarlimab (Jemperli) for adults with stage II or III locally advanced rectal ...

The FDA has accepted for review a new drug application (NDA) for UGN-103, an investigational intravesical formulation of ...

Ryan Moore, MD, discusses the choice between surgery and total neoadjuvant therapy (TNT) for rectal cancer and when watch-and ...

Selpercatinib (Retevmo), a selective oral RET inhibitor, demonstrated durable antitumor activity and a manageable safety ...

SABR improved recurrence-free survival vs historical benchmark with IVC tumor thrombus; investigators hypothesize this could ...

The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end ...

Ashley Rosko, MD, discusses how telehealth can improve access to myeloma transplant evaluation, reduce care disparities, and ...

Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether ...

Mogamulizumab (Poteligeo) was associated with durable real-world treatment outcomes in patients with mycosis fungoides (MF) ...

Platinum/etoposide regimens carry an intermediate risk of febrile neutropenia in extensive-stage small cell lung cancer ...

Texas Oncology’s virtual care navigation pilot supported 740 patients on oral oncolytics across 11 community sites, offering ...

Iyengar, MD, and participants discussed how approvals for trastuzumab deruxtecan before and after surgery complicate ...